$112 Million is the total value of Foresite Capital Management I, LLC's 2 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TXG | 10X Genomics, Inc. | $111,720,000 | +2.3% | 750,000 | 0.0% | 99.68% | +16.7% | |
| EPZM | Sell | Epizyme, Inc. | $359,000 | -76.1% | 143,759 | -51.1% | 0.32% | -72.8% |
| XLRN | Exit | Acceleron Pharma Inc. | $0 | – | -19,100 | -100.0% | -2.57% | – |
| NVAX | Exit | Novavax, Inc. | $0 | – | -66,810 | -100.0% | -10.84% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Acceleron Pharma Inc. | 16 | Q3 2021 | 43.0% |
| 10X Genomics, Inc. | 12 | Q3 2022 | 100.0% |
| Epizyme, Inc. | 8 | Q1 2022 | 1.7% |
| Orexigen Therapeutics, Inc. | 7 | Q3 2015 | 44.3% |
| BioDelivery Sciences International, Inc. | 7 | Q3 2015 | 29.3% |
| Karyopharm Therapeutics Inc. | 5 | Q4 2014 | 55.1% |
| Xencor, Inc. | 5 | Q4 2014 | 13.8% |
| Novavax, Inc. | 5 | Q3 2021 | 10.8% |
| Ignyta, Inc. | 5 | Q1 2015 | 15.4% |
| Ambit Biosciences Corporation | 4 | Q3 2014 | 30.7% |
View Foresite Capital Management I, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-13 |
| 13F-HR | 2020-08-13 |
View Foresite Capital Management I, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.